1. Home
  2. BSET vs MXCT Comparison

BSET vs MXCT Comparison

Compare BSET & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BSET

Bassett Furniture Industries Incorporated

HOLD

Current Price

$20.86

Market Cap

125.9M

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.33

Market Cap

136.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSET
MXCT
Founded
1902
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.9M
136.0M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
BSET
MXCT
Price
$20.86
$1.33
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
104.8K
1.6M
Earning Date
04-01-2026
05-12-2026
Dividend Yield
5.49%
N/A
EPS Growth
163.06
N/A
EPS
0.37
N/A
Revenue
$456,855,000.00
$33,026,000.00
Revenue This Year
$1.72
N/A
Revenue Next Year
$3.78
$18.50
P/E Ratio
$56.76
N/A
Revenue Growth
0.96
N/A
52 Week Low
$13.17
$0.64
52 Week High
$21.00
$2.37

Technical Indicators

Market Signals
Indicator
BSET
MXCT
Relative Strength Index (RSI) 76.09 67.92
Support Level $14.29 $1.19
Resistance Level N/A $1.81
Average True Range (ATR) 1.15 0.08
MACD 0.35 0.00
Stochastic Oscillator 93.45 85.26

Price Performance

Historical Comparison
BSET
MXCT

About BSET Bassett Furniture Industries Incorporated

Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: